AMG National Trust Bank Has $6.48 Million Stake in Kenvue Inc. (NYSE:KVUE)

AMG National Trust Bank increased its position in Kenvue Inc. (NYSE:KVUE) by 8.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 280,095 shares of the company’s stock after buying an additional 22,909 shares during the period. AMG National Trust Bank’s holdings in Kenvue were worth $6,479,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Riverview Trust Co bought a new stake in Kenvue in the third quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the 3rd quarter valued at $35,000. Deseret Mutual Benefit Administrators boosted its holdings in Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares in the last quarter. Studio Investment Management LLC increased its position in Kenvue by 52.1% during the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after buying an additional 845 shares during the last quarter. Finally, AlphaMark Advisors LLC acquired a new position in Kenvue during the third quarter worth $77,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KVUE. Piper Sandler upped their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. Bank of America raised their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. UBS Group increased their price objective on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $22.64.

Kenvue Stock Up 0.9 %

NYSE KVUE opened at $23.82 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $45.67 billion, a price-to-earnings ratio of 43.31, a PEG ratio of 2.16 and a beta of 1.36. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.13. The stock’s 50 day moving average is $22.77 and its two-hundred day moving average is $20.70.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the business posted $0.31 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. Equities analysts forecast that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.44%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is currently 149.09%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.